Background: Microglia are the resident immune cells of the central nervous system (CNS), related to the monocyte/macrophage lineage. In response to disease processes, microglia can acquire a wide range of morphological appearances hinting that they can perform different functions. Evidence from experimental models has helped to define specific functional phenotypes but it has become recognised that the response is complex and likely to be multidimensional. Genetic variation in innate immunity genes influences risk of Alzheimer's disease implicating microglia. We have explored in detail the role of microglia in human brain ageing and dementia using the MRC Cognitive Function and Ageing Study (CFAS). Methods: Inflammation was investigated in 298 cases using immunohistochemistry against microglial ionised calcium-binding adaptor molecule 1 (Iba-1), lysosome marker CD68, macrophage scavenger receptor A (MSR-A), Fcg receptor I (CD64) and the antigen presenting function HLA-DR. The data were analysed with regard to cognition, AD pathology (Ab and Tau) and APOE polymorphism. Results: Overall, MMSE was associated negatively with CD68 and HLA-DR and positively with CD64 and Iba1. Among the cases without dementia, associations were observed for: diffuse plaques with all markers except MSR-A. HLA-DR and Iba1 were negatively associated with tangles. In the cases with dementia and AD pathology, the strongest associations were observed between CD64 and diffuse plaques, CD68 and neurotic plaques and tangles, and MSR-A with neuritic plaques and tangles. With regard to the APOE polymorphism, ε2 was associated with expression of Iba1 and MSR-A and ε4 with CD68, CD64 and HLA-DR. Conclusions: Our findings indicate that different microglial populations coexist in the AD brain, with microglia responding differently to Ab and tau in subjects with and without dementia. Thus it is likely that microglial response influences the development of dementia. Interestingly, the findings suggest that APOE polymorphism is associated with the microglial profile. Background: The evolution of AD spans some 30 years, over much of which time symptoms are absent. This lack of available symptomatic endpoints is a fundamental problem for prevention research. Disease progression may be revealed, however, by various biomarkers that change over time. Preventive interventions can retard or halt this progression of pre-symptomatic disease (and its markers) thereby deferring the later onset of symptoms. In theory, therefore, pre-symptomatic biomarker trajectories can be used to select individuals for prevention trials and to identify preventive treatments with preliminary evidence in favor of their probable efficacy. Methods: Several issues confront longitudinal biomarker studies as indicators of pre-symptomatic disease progression: 1) we need validation of biomarker trajectories as true indicators of pathogenesis, i.e., of subsequent symptom onset; 2) we must identify which individual biomarkers are best suited to this purpose at various stages of disease development; and 3) we need analytic methods that can encompass the multiple metrics employed to reflect the disease progress while avoiding difficulties with multiple comparisons. Successful example applications of this approach will help demonstrate its value. Results: We present data from the BIO-CARD and Canadian PREVENT-AD studies, two programs that are currently characterizing the progression of biomarkers in persons at high risk of AD dementia. BIOCARD enrolled 349 cognitively normal persons at baseline and has obtained serial cerebrospinal fluid (CSF), neuroimaging and cognitive measures markers for up to 18 years. The study is examining (validating) these markers, either alone or combination, as predictors of subsequent symptom onset. PREVENT-AD has up to two years of biomarker data from 241 individuals with a parental history of AD. It assesses sensorineural abilities (olfaction, central auditory processing) as well as CSF and advanced neuroimaging markers as indicators of pre-symptomatic AD progression. It also includes a nested randomized, placebo-controlled biomarker-endpoint trial Podium Presentations: Sunday, July 19, 2015 P117
